San Antonio Breast Cancer Symposium 2017
San Antonio, Texas | December 05-09, 2017
SABCS is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.
Venue: Henry B. Gonzalez Convention Center
Date
December 05-09, 2017
Location
San Antonio, Texas, United States
Website
-
2:51Multidisciplinary management of locoregional breast cancer recurrenceLocoregional recurrences of breast cancers are rare, but when they do occur, can be challenging and typically require a multidisciplinary evaluation.
William Gradishar, MD -
6:34Early stage breast cancer: Appropriate margins for breast conserving surgerySheldon Feldman, MD, FACS, chief of breast surgery and breast surgical oncology, Montefiore-Einstein Cancer Center, New York, director of breast cancer services and professor...
Sheldon Feldman, MD, FACS -
1:29The future of breast cancer treatmentThe future of breast cancer treatment should center on risk-stratifying patients in a better way, according to Tatiana Prowell, MD, breast cancer scientific liaison, FDA...
Tatiana Prowell, MD -
0:52Value of chemotherapy for patients with locoregional breast cancer recurrenceIn patients with locoregional recurrence of breast cancer, the effects of chemotherapy are varied, depending on whether they have hormone receptor positive or hormone receptor...
William Gradishar, MD -
2:02Breast cancer: Mortality rates in men versus womenWhen we think of breast cancer, rarely do we consider the male patient, and it might be because “men are at a dramatically lower risk for breast cancer than...
Amy C. Degnim, MD -
1:11Breast imaging can predict cancer recurrenceAt the 2018 Best of SABCS-NY, Sheldon Feldman, MD, FACS, chief of breast surgery and breast surgical oncology, Montefiore-Einstein Cancer Center, New York, director of breast...
Sheldon Feldman, MD, FACS -
7:15Seamless designs for clinical trials: A new wave in drug development, explainedWith the movement toward developing more targeted therapies, the FDA has updated its drug development system to include what they have designated as ‘seamless...
Tatiana Prowell, MD -
2:14Breast cancer: Where we were and how far we’ve comeOver the past few decades, great progress has been made in the field of breast cancer, according to Tatiana Prowell, MD, breast cancer scientific liaison, FDA Oncology Center...
Tatiana Prowell, MD -
2:34Are clinical trials representative of a broader patient population?In clinical trials for cancer drug development, researchers have been enrolling patients who are otherwise healthy; patients who are asymptomatic, and have free mobility. By...
Tatiana Prowell, MD -
3:02How to approach your patients to improve adherence to therapyWith recent approvals for new oral mTOR and CDK 4/6 inhibitors, patients with cancer are more responsible for treatment adherence, and it is important to keep the lines of...
Angela DeMichele, MD, MSCE -
1:50Tumor types, immune response, and radiotherapyOne of the most exciting areas of study currently being conducted in breast cancer is the potential of radiation therapy to convert tumors into an in situ vaccine. Silvia...
Silvia Formenti, MD -
0:52Value of chemotherapy for patients with locoregional breast cancer recurrence
Although chemotherapy can positively impact patient outcomes after locoregional recurrence of breast cancer, this will generally occur only in patients with HR-negative (HR-)...
William Gradishar, MD -
3:14Managing patients with high risk breast lesionsAmy C. Degnim, MD, professor of surgery, Mayo Clinic, Rochester, MN, discusses the different management strategies for lesions that put patients at increased risk for breast...
Amy C. Degnim, MD -
2:36A look back at SABCS 2017: Overtreatment can result in lifelong complicationsResearchers from around the world gathered at the 2017 San Antonio Breast Cancer Symposium to present research that would change the way we view breast cancer.
Sheldon Feldman, MD, FACS -
4:40Implementing the TEAM approach to optimize concurrent palliative careOncologists should be open to implementing the TEAM approach to provide their patients the best concurrent palliative care possible, Thomas J. Smith, MD, FACP, FASCO, FAAHPM,...
Thomas J. Smith, MD, FACP, FASCO, FAAHPM -
4:24Helping your patient feel in control through effective communication in palliative carePalliative care is an important tool in helping your patient overcome the stress associated with dealing with their disease and symptoms. Unfortunately, however, there is a...
Thomas J. Smith, MD, FACP, FASCO, FAAHPM -
5:57Exploring locoregional recurrence of breast cancerFor locoregional recurrence of breast cancer, there is no standard of care because there are so few patients in whom this occurs.
William Gradishar, MD -
1:32The promise of radiotherapyExploring the interaction between radiation therapy and immunotherapy in enhancing responses to treatment in breast cancer patients is currently one of the main research...
Silvia Formenti, MD -
1:15The paradoxical role of family history in breast cancer riskAlthough family history can influence a patient’s risk of developing breast cancer, it does not increase that risk once other risk factors are identified.
Amy C. Degnim, MD -
2:34Estrogen receptor expression in luminal tumors & recurrence and metastasisLuminal breast cancer subtypes are characterized by estrogen-receptor and estrogen-related genes, which sets them apart from other tumors that are not hormonally driven.
Angela DeMichele, MD, MSCE -
1:50Conversion to response after failed immunotherapyIn some patients with cancer who have failed immune checkpoint blockade treatment, the addition of radiotherapy may bring about conversion to response.
Silvia Formenti, MD -
1:32The benefits and hurdles of early, concurrent, palliative careThe difference between hospice care and palliative care is an important distinction to make, and the shortage in palliative care providers must be addressed if clinicians are...
Thomas J. Smith, MD, FACP, FASCO, FAAHPM -
3:22Luminal breast cancer: Additional interventions and patient adherenceWith estrogen-responsive luminal A and Luminal B metastatic tumors, there is often no distinction in the treatment of disease, which often involves an anti-estrogen. However,...
Angela DeMichele, MD, MSCE -
1:47Evaluating the risk of breast cancer among female patientsThere are several factors that put female patients at an increased risk for breast cancer.
Amy C. Degnim, MD -
4:23Circulating tumor cells as prognostic biomarkers for recurrence of breast cancerAt the 2018 Best of San Antonio Breast Cancer Symposium-New York, Joseph Sparano, MD, professor of medicine and women’s health, Albert Einstein College of Medicine,...
Joseph A. Sparano, MD
This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium 2017.